Disease Overview：Hyperuricemia（HUA）
Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid levels—typically exceeding 6.8 mg/dL—due to either overproduction or underexcretion of uric acid. It serves as the biochemical precursor to gout, nephrolithiasis, and chronic kidney disease, and is increasingly recognized as an independent risk factor for cardiovascular morbidity and insulin resistance. While often asymptomatic initially, persistent hyperuricemia can trigger acute inflammatory arthritis, urate nephropathy, and progressive renal impairment. Diagnosis relies on fasting serum uric acid measurement, supplemented by 24-hour urinary uric acid excretion, renal function assessment (eGFR, serum creatinine), and imaging when complications such as tophi or nephroliths are suspected. Management emphasizes lifestyle modification—dietary purine restriction, alcohol limitation, weight optimization—and pharmacotherapy including xanthine oxidase inhibitors (e.g., febuxostat, allopurinol) or uricosurics (e.g., benzbromarone), tailored to renal function and comorbidities like hypertension or diabetes mellitus.
China offers distinct advantages in hyperuricemia care: its endocrinology departments integrate evidence-based protocols with advanced diagnostics—including dual-energy CT for early tophus detection and high-sensitivity uric acid assays—and maintain robust clinical registries demonstrating sustained urate-lowering efficacy (>90% target attainment at 6 months in tertiary centers). Treatment costs remain significantly lower than in the US, UK, or Germany—often 40–60% less for comprehensive evaluation and 12-month pharmacologic management—without compromising quality or safety standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with nationally certified endocrinologists, verifying hospital accreditation (JCI or CNAS), providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hyperuricemia (Endocrinology Department)
Non-Surgical / Conservative / Medication Management
*Target Criteria:* Asymptomatic hyperuricemia (serum uric acid ≥420 μmol/L in men, ≥360 μmol/L in women), recurrent gout flares (<2/year), or early chronic kidney disease (eGFR ≥60 mL/min/1.73m²).
- •Initial Workup (Mandatory):
- Renal function panel (creatinine, eGFR, BUN): $15–$22 - Urinary uric acid excretion (24-hr collection): $28–$35 - Liver function test + lipid profile: $22–$30 - *Total baseline lab cost: $73–$100*
- •Tiered Pharmacotherapy (30-day supply, oral):
- *First-line (XOI):* Febuxostat 40 mg/day — $32–$44 - *Second-line (XOI):* Allopurinol 300 mg/day (dose-adjusted per eGFR) — $6–$10 - *Acute flare prophylaxis:* Low-dose colchicine (0.5 mg BID × 6 months) — $12–$18 - *Lifestyle counseling (endocrinology nurse visit, 30 min):* $25–$35
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Refractory to ≥6 months of dual-drug therapy (e.g., febuxostat + probenecid), serum uric acid >540 μmol/L with tophaceous gout (≥2 visible tophi), or uric acid nephrolithiasis with obstructive uropathy confirmed by CT KUB.
- •Preoperative Workup:
- Cardiopulmonary assessment (ECG + chest X-ray): $22–$30 - Coagulation panel + HbA1c (if diabetic): $28–$38 - *Total pre-op cost: $135–$183*
- •Procedures (per session, endocrinology-coordinated with urology/rheumatology):
- *Uric acid stone fragmentation (extracorporeal shockwave lithotripsy, ESWL):* $950–$1,420 - *Chronic hemodialysis adjunct (for CKD Stage 4–5 with persistent hyperuricemia):* $180–$240/session (requires ≥3 sessions/month)
Special / Complex Condition Management
- •Severe CKD (eGFR <30 mL/min): Rasburicase IV (single 1.5 mg dose, reserved for tumor lysis syndrome–related hyperuricemia): $1,650–$2,100
- •Genetic PHPT comorbidity (e.g., PRPS1 mutation): Long-term pegloticase infusions (biweekly, 8 mg IV): $4,200–$5,300/dose, plus mandatory pre-infusion uricase antibody testing ($110) and infusion monitoring ($140/session)
Quick Selection Guide
- •<45 years, no comorbidities, UA 480–520 μmol/L: Start allopurinol + lifestyle counseling ($31–$45 total/month)
- •Age 65+, T2D + eGFR 45–59 mL/min: Febuxostat 20 mg + renal-sparing colchicine ($44–$62/month)
- •Tophaceous gout + obstructive stones: ESWL + febuxostat ($1,000–$1,500 initial outlay, then $44+/month)
- •Budget-constrained (≤$500/year): Allopurinol + strict dietary intervention ($72–$120/year medication + $25–$35 counseling)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hyperuricemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Hyperuricemia treatment with China top medical destinations:
